Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 28;7(1):28.
doi: 10.1038/s41392-022-00880-9.

SARS-CoV-2 variant Omicron: currently the most complete "escapee" from neutralization by antibodies and vaccines

Maochen Li #  1 , Fuxing Lou #  1 , Huahao Fan  2
Affiliations
Comment

SARS-CoV-2 variant Omicron: currently the most complete "escapee" from neutralization by antibodies and vaccines

Maochen Li et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A schematic illustration of the variant Omicron escaping approved antibodies and vaccines. a FDA has approved several S protein-targeted monoclonal antibodies, in which Bamlanivimab, Etesevimab, Casirivimab, Imdevimab and CT-P59 (Regdanvimab) as well as the serum of all kinds of 2nd vaccine dose, fail to neutralize Omicron variant, while Sotrovimab and convalescent plus vaccinated plasma maintain the efficacy of Omicron variant. b Amino acid substitutions of Omicron variant in the spike protein, some of these mutations in RBD may affect the neutralization activity of group A–F antibodies, respectively. c The neutralizations of seven approved antibodies (Tixagevimab, Cilgavimab, Sotrovimab, Bamlanivimab, Etesevimab, Casirivimab, and Imdevimab) and six vaccines (BNT162b2, mRNA-1273, AZD1222, Sputnik V, BBIBP-CorV, Ad26.COV2.S) against Omicron are displayed, among which Bamlanivimab, Etesevimab, Casirivimab, and Imdevimab completely lose the neutralization while Sotrovimab still can neutralize Omicron variant effectively. All the 1st and 2nd dose vaccine serum fail to neutralize Omicron variant, and both the serum from convalescent patient with vaccination and booster dose of BNT162b2 retain neutralization activity against Omicron variant
See this image and copyright information in PMC

Comment on

  • Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Cao Y, et al. Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23. Nature. 2022. PMID: 35016194 Free PMC article.
  • Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O. Planas D, et al. Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23. Nature. 2022. PMID: 35016199

References

    1. Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature10.1038/d41586-021-03796-6 (2021). - PMC - PubMed
    1. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature10.1038/d41586-02103827-2 (2021). - PubMed
    1. Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature10.1038/d41586-02103826-3 (2021). - PubMed
    1. Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature10.1038/d41586-021-03824-5 (2021). - PMC - PubMed
    1. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature10.1038/d41586-02103825-4 (2021). - PMC - PubMed

Publication types

Supplementary concepts